Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
作者信息
Schlam Ilana, Tolaney Sara M
出版信息
Oncotarget. 2021 Apr 27;12(9):873-875. doi: 10.18632/oncotarget.27904.
Abstract
摘要
相似文献
1
Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?CDK 4/6抑制剂在乳腺癌脑转移中是否发挥作用？
Oncotarget. 2021 Apr 27;12(9):873-875. doi: 10.18632/oncotarget.27904.
2
The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers.成人实体癌软脑膜转移的潜在生物学特性及治疗脆弱性
Cancers (Basel). 2021 Feb 10;13(4):732. doi: 10.3390/cancers13040732.
3
CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.CDK4/6 抑制剂联合立体定向放疗治疗激素受体阳性乳腺癌脑转移
J Neurooncol. 2019 Sep;144(3):583-589. doi: 10.1007/s11060-019-03260-6. Epub 2019 Aug 9.
4
Breast brain metastases are associated with increased risk of leptomeningeal disease after stereotactic radiosurgery: a systematic review and meta-analysis.脑转移瘤与立体定向放射外科后发生脑膜疾病的风险增加相关：系统评价和荟萃分析。
Clin Exp Metastasis. 2020 Apr;37(2):341-352. doi: 10.1007/s10585-020-10019-1. Epub 2020 Jan 16.
5
Management of breast cancer brain metastases.乳腺癌脑转移的管理
Chin Clin Oncol. 2018 Jun;7(3):30. doi: 10.21037/cco.2018.05.06.
6
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).CDK4/6 抑制剂在激素受体阳性、人表皮生长因子受体 2 阴性、转移性乳腺癌中的应用：乳腺癌治疗专家小组（BCTEG）的圆桌讨论。
Breast Cancer Res Treat. 2018 Aug;171(1):11-20. doi: 10.1007/s10549-018-4783-1. Epub 2018 May 4.
7
The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases.柔脑膜转移瘤中手术治疗脑积水的预后意义
Clin Neurol Neurosurg. 2014 Apr;119:80-3. doi: 10.1016/j.clineuro.2014.01.023. Epub 2014 Jan 28.
8
Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.伴有软脑膜转移的乳腺癌患者的特征与预后
Clin Breast Cancer. 2017 Feb;17(1):23-28. doi: 10.1016/j.clbc.2016.07.002. Epub 2016 Jul 25.
9
Targeted Therapies for Brain Metastases from Breast Cancer.乳腺癌脑转移的靶向治疗
Int J Mol Sci. 2016 Sep 13;17(9):1543. doi: 10.3390/ijms17091543.
10
Targeting breast cancer with CDK inhibitors.使用细胞周期蛋白依赖性激酶（CDK）抑制剂治疗乳腺癌。
Curr Oncol Rep. 2015;17(5):443. doi: 10.1007/s11912-015-0443-3.
引用本文的文献
1
Unusual presentation of luminal breast carcinoma metastatic to the brain and coma: a case report of dramatic response to abemaciclib and literature review.管腔型乳腺癌脑转移并昏迷的罕见表现：一例对阿贝西利有显著反应的病例报告及文献综述
Ther Adv Med Oncol. 2025 Mar 28;17:17588359251317847. doi: 10.1177/17588359251317847. eCollection 2025.
2
Recent progress of CDK4/6 inhibitors' current practice in breast cancer.CDK4/6抑制剂在乳腺癌当前治疗中的最新进展
Cancer Gene Ther. 2024 Sep;31(9):1283-1291. doi: 10.1038/s41417-024-00747-x. Epub 2024 Feb 26.
3
Successful management of bilateral orbital metastases from invasive lobular breast cancer with abemaciclib and letrozole: a case report and literature review.阿贝西利联合来曲唑成功治疗浸润性小叶乳腺癌双侧眼眶转移：一例报告及文献综述
Front Oncol. 2024 Jan 23;14:1286910. doi: 10.3389/fonc.2024.1286910. eCollection 2024.
4
Systematic review of the management of brain metastases from hormone receptor positive breast cancer.激素受体阳性乳腺癌脑转移的管理：系统评价。
J Neurooncol. 2023 Mar;162(1):45-57. doi: 10.1007/s11060-023-04276-9. Epub 2023 Mar 8.
5
Anti-Hormonal Therapy in Breast Cancer and Its Effect on the Blood-Brain Barrier.乳腺癌的抗激素治疗及其对血脑屏障的影响。
Cancers (Basel). 2022 Oct 19;14(20):5132. doi: 10.3390/cancers14205132.
6
Intracranial Metastatic Disease: Present Challenges, Future Opportunities.颅内转移性疾病：当前挑战与未来机遇
Front Oncol. 2022 Mar 7;12:855182. doi: 10.3389/fonc.2022.855182. eCollection 2022.
本文引用的文献
1
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.阿贝西利治疗激素受体阳性乳腺癌脑转移患者的 II 期研究。
Clin Cancer Res. 2020 Oct 15;26(20):5310-5319. doi: 10.1158/1078-0432.CCR-20-1764. Epub 2020 Jul 21.
2
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial.曲妥珠单抗-美坦新偶联物（T-DM1）治疗人表皮生长因子受体 2 阳性转移性乳腺癌伴脑转移患者：来自 KAMILLA 研究队列 1 的探索性最终分析，一项单臂 IIIb 期临床研究。
Ann Oncol. 2020 Oct;31(10):1350-1358. doi: 10.1016/j.annonc.2020.06.020. Epub 2020 Jul 5.
3
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.在 HER2CLIMB 试验中，曲妥珠单抗联合卡培他滨治疗既往治疗的 HER2 阳性乳腺癌伴脑转移的颅内疗效和生存。
J Clin Oncol. 2020 Aug 10;38(23):2610-2619. doi: 10.1200/JCO.20.00775. Epub 2020 May 29.
4
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.阿贝西利联合曲妥珠单抗和（或）氟维司群对比曲妥珠单抗联合标准治疗化疗用于激素受体阳性、HER2 阳性晚期乳腺癌患者（monarcHER）：一项随机、开放标签、二期临床试验。
Lancet Oncol. 2020 Jun;21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1. Epub 2020 Apr 27.
5
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.曲妥珠单抗、曲妥珠单抗和卡培他滨治疗人表皮生长因子受体 2 阳性转移性乳腺癌。
N Engl J Med. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11.
6
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.阿贝西利联合氟维司群治疗激素受体阳性、HER2 阴性乳腺癌的疗效：内分泌治疗进展后总生存的影响——MONARCH 2 随机临床试验
JAMA Oncol. 2020 Jan 1;6(1):116-124. doi: 10.1001/jamaoncol.2019.4782.
7
How we treat patients with leptomeningeal metastases.我们如何治疗软脑膜转移患者。
ESMO Open. 2019 May 21;4(Suppl 2):e000507. doi: 10.1136/esmoopen-2019-000507. eCollection 2019.
8
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.MONARCH 3最终无进展生存期：阿贝西利作为晚期乳腺癌初始治疗的随机研究。
NPJ Breast Cancer. 2019 Jan 17;5:5. doi: 10.1038/s41523-018-0097-z. eCollection 2019.
9
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.MONARCH 2 研究：阿贝西利联合氟维司群治疗 HR+/HER2-晚期乳腺癌患者的疗效，这些患者在接受内分泌治疗时发生了进展。
J Clin Oncol. 2017 Sep 1;35(25):2875-2884. doi: 10.1200/JCO.2017.73.7585. Epub 2017 Jun 3.
10
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR/HER2 Metastatic Breast Cancer.MONARCH 1 研究：阿贝西利（一种 CDK4 和 CDK6 抑制剂）单药治疗难治性 HR/HER2 转移性乳腺癌的 II 期研究。
Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22.
Zotero 插件